Genetic Ablation and Pharmacological Blockade of Bradykinin B1 Receptor Unveiled a Detrimental Role for the Kinin System in Chagas Disease Cardiomyopathy
- PMID: 37109224
- PMCID: PMC10144326
- DOI: 10.3390/jcm12082888
Genetic Ablation and Pharmacological Blockade of Bradykinin B1 Receptor Unveiled a Detrimental Role for the Kinin System in Chagas Disease Cardiomyopathy
Abstract
Chagas disease, the parasitic infection caused by Trypanosoma cruzi, afflicts about 6 million people in Latin America. Here, we investigated the hypothesis that T. cruzi may fuel heart parasitism by activating B1R, a G protein-coupled (brady) kinin receptor whose expression is upregulated in inflamed tissues. Studies in WT and B1R-/- mice showed that T. cruzi DNA levels (15 days post infection-dpi) were sharply reduced in the transgenic heart. FACS analysis revealed that frequencies of proinflammatory neutrophils and monocytes were diminished in B1R-/- hearts whereas CK-MB activity (60 dpi) was exclusively detected in B1R+/+ sera. Since chronic myocarditis and heart fibrosis (90 dpi) were markedly attenuated in the transgenic mice, we sought to determine whether a pharmacological blockade of the des-Arg9-bradykinin (DABK)/B1R pathway might alleviate chagasic cardiomyopathy. Using C57BL/6 mice acutely infected by a myotropic T. cruzi strain (Colombian), we found that daily treatment (15-60 dpi) with R-954 (B1R antagonist) reduced heart parasitism and blunted cardiac injury. Extending R-954 treatment to the chronic phase (120-160 dpi), we verified that B1R targeting (i) decreased mortality indexes, (ii) mitigated chronic myocarditis, and (iii) ameliorated heart conduction disturbances. Collectively, our study suggests that a pharmacological blockade of the proinflammatory KKS/DABK/B1R pathway is cardioprotective in acute and chronic Chagas disease.
Keywords: Chagas disease; GPCRs; Trypanosoma cruzi; bradykinin; kallikrein.
Conflict of interest statement
The authors declare no conflict of interest.
Figures





References
-
- Nunes M.C.P., Beaton A., Acquatella H., Bern C., Bolger A.F., Echeverria L.E., Dutra W.O., Gascon J., Morillo C.A., Oliveira-Filho J., et al. Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association. Circulation. 2018;138:e169–e209. doi: 10.1161/CIR.0000000000000599. - DOI - PubMed
-
- Ribeiro Dos Santos R., Rassi S., Feitosa G., Grecco O.T., Rassi A., Jr., da Cunha A.B., de Carvalho V.B., Guarita-Souza L.C., de Oliveira W., Jr., Tura B.R., et al. Cell therapy in Chagas cardiomyopathy (Chagas arm of the multicenter randomized trial of cell therapy in cardiopathies study): A multicenter randomized trial. Circulation. 2012;125:2454–2461. doi: 10.1161/CIRCULATIONAHA.111.067785. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous